BC Platforms (BCP), a global leader in real world data, healthcare data management, and analytics, today announces an exclusive collaboration with NTT Life Science Corporation, a company in the medical field of the NTT Group, to accelerate data-driven medicine. Last week, in Japan, an official opening ceremony of a joint Tokyo facility was held, housed within NTT Life Science, which will drive and develop the Japan Precision Medicine PlatformTM (JPP). This marked the concrete beginning of the global partnership. The JPP has the power, for the first time in Japan to enable the usage of clinical data, ensuring the safe and efficient access, sharing and analysis of this data across the nation. JPP is a national medical data distribution platform to integrate, curate, and harmonize Japanese healthcare data enabled by BCP’s technology integrated with NTT’s global network and technology. For official ceremony photos see (1).
This multiyear collaboration, announced on October 2023 (2), now gives exclusive rights in the Japanese market, under the JPP. The enablement of this technology in a multitenant model, where a single instance of a software application serves multiple customers, will introduce a national medical data distribution platform to integrate, curate, and harmonize Japanese healthcare data. This JPP will provide a safe & secure data collaboration environment where researchers can work across organizations, accelerating the development of new therapies, from oncology to rare diseases. The primary goal of the partnership is to provide a positive impact on patients through personalized medicine, through better use of real-world data (RWD), including identifying patients suitable for clinical trials.
“We are delighted that NTT Life Science will exclusively represent our technology in Japan. This powerful strategic partnership with NTT Group is a core element of our mission to be a leading real-world data, technology, and services provider,” said BCP’s Chairman of the Board, Laurent Samama. “By collaborating with one of the world’s largest technology companies, we boost our ability to scale, and maximize, the value of our capabilities, as we build the world’s largest health data network.”
The partnership aims to create a system to enable better utilization of data through collaboration with government agencies and companies. It addresses Japan’s rising medical costs and need for innovation in healthcare. By making RWD more accessible, the platform will support developing new therapies in a data-driven, evidence-based approach. It brings together four organizations based in Tokyo: NTT; NTT Life Science Corporation; New Medical Real World Data Research Organization Inc. (PRiME-R); and Bio-Xcelerator, Inc. The goal is to implement services by NTT Life Science built on BCP’s technology.
“In the NTT Group medium-term management strategy ‘New value creation & Sustainability 2027 powered by IOWN’ (announced in May 2023) (3), we announced that we will proceed with new value creation through data-driven technology. One of our representative initiatives is this JPP. We would like to quickly create a market together with BCP, which has a global track record in the medical field, which is a growing market and an investment field for NTT,” said Akiko Kudo, Nippon Telegraph and Telephone Corporation, Senior Vice President, Head of Alliance Department, Research and Development Market Strategy Division, and Member of the Board of the Company.
“We are committed to making a difference in precision medicine, by harnessing powerful data-driven insights. Our ambition is to transform global healthcare solutions, starting from Japan, where we have extensive experience in medical research. 47 medical institutions are engaged with PRiME-R for using CyberOncology®, and Genovision Dock® (4) is available in 59 medical institutions. In total, over 80,000 customers have been examined. We will leverage this strength to promote JPP,” said Kouji Korekawa, President and CEO of NTT Life Science and President of PRiME-R.
“With NTT’s innovative capabilities, we can offer global pharma companies access to real-world data, making it easier, faster, and more complete than any other alternative. We are delighted to be forming a combined, localized, team in Tokyo, in this unprecedented partnership with JPP, which will become a massive global medical data highway. NTT Life Science & PRiME-R have the network, the servers, the sites, and the know-how. Basically, they have everything right, and at scale too: the NTT Global Data Centre is the third largest data center operator in the market (5). We will add our technology onto their unmatched system and build the multi-tenant system that can supply any organization in Japan with our system for managing and harmonizing and analyzing their data and working on research on their data,” said Nino da Silva, Managing Director APAC at BC Platforms.
Image:
Source NTT. From left:
Ken Matsuzak, VP, Head of Healthcare & Medical Business Planning Office, Nippon Telegraph and Telephone Corporation
Hideki Tsukuda, SVP, Member of the Board, NTT Life Science
Kouji Korekawa, President and CEO, NTT Life Science and President, PRiME-R
Kaj Työppönen, CFO, BC Platforms
Laurent Samama, Chairman of the Board, BC Platforms
Akiko Kudo, SVP, Head of Alliance Department, Research and Development Market Strategy Division, Member of the Board, Nippon Telegraph and Telephone Corporation
Nino da Silva, Managing Director APAC, BC Platforms
Masaaki Tabata, VP of Life Innovation Department and Member of the Board, NTT Life Science
References
(1): Official photographs from the opening ceremony: https://4611778.fs1.hubspotusercontent-na1.net/hubfs/4611778/NTT%20Presser%202%20Ceremony%20image%20web.jpg
(2): First press releases announcing the collaboration:
https://www.bcplatforms.com/news/bc-platforms-partners-with-ntt-to-accelerate-data-driven-medicine-in-japan
https://group.ntt/en/newsrelease/2023/10/03/231003a.html
(3): New value creation & Sustainability 2027 powered by IOWN: https://group.ntt/jp/ir/mgt/managementstrategy/
(4): About Genovision®: https://service.ntt-lifescience.co.jp/rpts/anonymous/aboutdna
(5): NTT IR DAY October 3, 2023: https://group.ntt/en/ir/library/presentation/institutional/
-Ends-
About NTT
NTT contributes to a sustainable society through the power of innovation. We are a leading global technology company providing services to consumers and businesses as a mobile operator, infrastructure, networks, applications, and consulting provider. Our offerings include digital business consulting, managed application services, workplace and cloud solutions, data center and edge computing, all supported by our deep global industry expertise. We are over $97B in revenue and 330,000 employees, with $3.6B in annual R&D investments. Our operations span across 80+ countries and regions, allowing us to serve clients in over 190 of them. We serve over 75% of Fortune Global 100 companies, thousands of other enterprise and government clients and millions of consumers.
